| Identification | Back Directory | [Name]
BenzenepentanaMide, N-[[3-Methoxy-4-(phenylMethoxy)phenyl]Methyl]-N-[2-(2-pyridinyl)ethyl]- | [CAS]
521310-51-0 | [Synonyms]
MCP110
N-(4-(benzyloxy)-3-Methoxybenzyl)-5-phenyl-N-(2-(pyridin-2-yl)ethyl)pentanaMide
BenzenepentanaMide, N-[[3-Methoxy-4-(phenylMethoxy)phenyl]Methyl]-N-[2-(2-pyridinyl)ethyl]- | [Molecular Formula]
C33H36N2O3 | [MDL Number]
MFCD28405026 | [MOL File]
521310-51-0.mol | [Molecular Weight]
508.65 |
| Hazard Information | Back Directory | [Description]
MCP110 is an inhibitor of the protein-protein interaction between Ras and Raf-1.1 It inhibits the interaction between H-Ras and Raf-1 in a yeast two-hybrid assay when used at a concentration of 30 µM. MCP110 (20 µM) inhibits Ras-induced activation of Raf-1 and MEK1 activity in HT-1080 fibrosarcoma cells. In vivo, MCP110 (100 and 600 mg/kg) reduces tumor volume in an SW620 colorectal cancer mouse xenograft model when administered alone or in combination with paclitaxel (Item No. 10461).2WARNING This product is not for human or veterinary use. | [References]
[1] JURAN KATO-STANKIEWICZ. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99 22: 14398-14403. DOI: 10.1073/pnas.222222699
[2] NATALIA SKOBELEVA. In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.[J]. Molecular Cancer Therapeutics, 2007, 6 3: 898-906. DOI: 10.1158/1535-7163.mct-06-0602 |
|
|